New Leadership and Strategic Hire
Dr. Richard Goldberg, a world-renowned GI-Oncology expert, has joined as the Chief Development Officer to steer regulatory paths for new therapies.
Operational Efficiency and Financial Strategy
Operational cash burn is on track to be cut below $50 million annualized in the second half of 2025. Four formal transaction proposals received, including a significant equity investment at a premium and licensing deals to strengthen the balance sheet.
Positive BOT/BAL Study Results
Consistent and compelling data across different lines of treatment in multiple cold tumors, with presentations at AACR 2025 showing durable responses.
Increased Phase 1 and Phase 2 Follow-Up
Phase 1 trial median follow-up is now 18 months with 123 patients, and Phase 2 trial median follow-up is over 12 months, with substantial data maturity.